FCCC LOGO Faculty Publications
Tuttle RM , Haddad RI , Ball DW , Byrd D , Dickson P , Duh QY , Ehya H , Haymart M , Hoh C , Hunt JP , Iagaru A , Kandeel F , Kopp P , Lamonica DM , Lydiatt WM , McCaffrey J , Moley JF , Parks L , Raeburn CD , Ridge JA , Ringel MD , Scheri RP , Shah JP , Sherman SI , Sturgeon C , Waguespack SG , Wang TN , Wirth LJ , Hoffmann KG , Hughes M
Thyroid carcinoma, version 2.2014
J Natl Compr Canc Netw. 2014 Dec;12(12) :1671-80
PMID: 25505208   
Back to previous list
Abstract
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.
Notes
1540-1413 Tuttle, R Michael Haddad, Robert I Ball, Douglas W Byrd, David Dickson, Paxton Duh, Quan-Yang Ehya, Hormoz Haymart, Megan Hoh, Carl Hunt, Jason P Iagaru, Andrei Kandeel, Fouad Kopp, Peter Lamonica, Dominick M Lydiatt, William M McCaffrey, Judith Moley, Jeffrey F Parks, Lee Raeburn, Christopher D Ridge, John A Ringel, Matthew D Scheri, Randall P Shah, Jatin P Sherman, Steven I Sturgeon, Cord Waguespack, Steven G Wang, Thomas N Wirth, Lori J Hoffmann, Karin G Hughes, Miranda Journal Article United States J Natl Compr Canc Netw. 2014 Dec;12(12):1671-80.